Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Salido-Vallejo, R. (Rafael) | - |
dc.creator | Sanz-Cabanillas, J.L. (Juan Luis) | - |
dc.creator | Nuñez-Cordoba, J.M. (Jorge M.) | - |
dc.creator | González-Menchen, A. (Alberto) | - |
dc.creator | Vélez, A. (Antonio) | - |
dc.creator | Redondo-Bellón, P. (Pedro) | - |
dc.date.accessioned | 2022-03-15T08:36:04Z | - |
dc.date.available | 2022-03-15T08:36:04Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Salido-Vallejo, R. (Rafael); Sanz-Cabanillas, J.L. (Juan Luis); Nuñez-Cordoba, J.M. (Jorge M.); et al. "Clinical utility of intralesional methotrexate to distinguish crateriform keratinocytic tumors before surgery". Journal der Deutschen Dermatologischen Gesellschaft. 20 (1), 2021, 102 - 105 | es |
dc.identifier.issn | 1610-0387 | - |
dc.identifier.uri | https://hdl.handle.net/10171/63221 | - |
dc.description.abstract | Clinical utility of intralesional methotrexate to distinguish crateriform keratinocytic tumors before surgeryDear Editors,Keratoacanthoma (KA) and cutaneous squamous cell carci-noma (CSCC) may adopt an identical crateriform morpho-logy. Nowadays, the debate about whether KA is a distinct entity, or a low-grade variant of cutaneous squamous cell carcinoma (CSCC) still persists. Since CSCC is a more ag-gressive neoplasm, misdiagnosing crateriform lesions may have a negative impact on the patient's prognosis. Evaluating a partial biopsy is extremely challenging to confidently dis-tinguish KA from CSCC [1]. No distinctive gene expression profiles have been identified and no pathognomonic criteria to unequivocally differentiate between KA and CSCC exist [2]. Consequently, the surgical approach remains the gold standard in the management of crateriform tumors, especi-ally those arising on the face. | es_ES |
dc.description.sponsorship | Open access funding enabled and organized by Projekt DEAL | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Materias Investigacion::Ciencias de la Salud::Dermatología | es_ES |
dc.title | Clinical utility of intralesional methotrexate to distinguish crateriform keratinocytic tumors before surgery | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs Licens | es_ES |
dc.identifier.doi | 0.1111/ddg.14637 | - |
dadun.citation.endingPage | 105 | es_ES |
dadun.citation.number | 1 | es_ES |
dadun.citation.publicationName | Journal der Deutschen Dermatologischen Gesellschaft | es_ES |
dadun.citation.startingPage | 102 | es_ES |
dadun.citation.volume | 20 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.